Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After J&J Vaccine Pause, Urgent Safety Questions for Sputnik And CanSino On Possible ‘Class Effect’

Executive Summary

Potentially fatal blood clots seen in AZ and J&J’s COVID-19 vaccine could be common to all adenovirus vector vaccines – but Russia and China developers are dismissing a possible link.

You may also be interested in...



US FDA’s Search For Class-Wide Vaccine Blood-Clot Effect Makes Scientific Sense, But Raises Questions

Several adenovirus vaccine developers say the products cannot be compared, potentially complicating the US FDA and CDC’s decision on ending the recommended pause in the use of Janssen’s vaccine.

J&J COVID-19 Vaccine Rollout Resumes In EU With New Rare Blood Clot Warning

Similarities to AstraZeneca blood clots are clear, but more research needed before any ‘class effect’ conclusions can be drawn.

Coronavirus Notebook: WHO’s Plan For Vaccine Manufacturing In Lower-Income Countries, UK Urged To Back IP Waiver

The UK’s independent vaccines committee has finalized its recommendations for the second phase of the COVID-19 vaccination program, and safety issues with several vaccines are still hitting the headlines.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel